
Hot on heels of a positive PhIII, Ablynx files $150M IPO; Shire sues Allergan over dry eye drug rivalry
→ After watching its European share price surge {$ABLX BB} yesterday on positive Phase III data, Ablynx feels it’s perfect timing for an IPO on Nasdaq. The Belgian biotech is looking to raise around $150 million at a time a growing number of European biotechs have been finding a warm welcome on the exchange. The group is pushing a new drug for acquired thrombotic thrombocytopenic purpura, or aTTP.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.